A new clinical trial led by scientists at the Yale School of Medicine is testing whether targeting inflammation in people at high risk of Parkinson's disease can prevent or slow disease development. In the PRISMS study (NCT06996652), which recently enrolled its first participant, researchers are testing adalimumab, an anti-inflammatory medication sold under the brand name […]
A new clinical trial led by scientists at the Yale School of Medicine is testing whether targeting inflammation in people at high risk of Parkinson's disease can prevent or slow disease development.
In the PRISMS study (NCT06996652), which recently enrolled its first participant, researchers are testing adalimumab, an anti-inflammatory medication sold under the brand name […]
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
A new clinical trial led by scientists at the Yale School of Medicine is testing whether targeting inflammation in people at high risk of Parkinson's disease can prevent or slow disease development. In the PRISMS study (NCT06996652), which recently enrolled its first participant, researchers are testing adalimumab, an anti-inflammatory medication sold under the brand name […]
Open the app view to save this story, compare related coverage, and continue from the same source.